SCHEMBL4666497

SCHEMBL4666497

COCn1c(C)nc2c(OCc3ccccc3)cc(C(=O)N(C)C)cc21

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 2/20 0.47
NPC1 O15118 1/20 0.41
HPGD P15428 1/20 0.41
RAB9A P51151 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
LRRK2 Q5S007 1/20 0.40
APP P05067 3/20 0.39
F2 P00734 2/20 0.39
F10 P00742 2/20 0.39
SMPD1 P17405 1/20 0.38
HDAC1 Q13547 1/20 0.38
HDAC8 Q9BY41 1/20 0.38
HDAC6 Q9UBN7 1/20 0.38
SRD5A1 P18405 1/20 0.38
SRD5A2 P31213 1/20 0.38
MRGPRX4 Q96LA9 1/20 0.38
CYP11B1 P15538 1/20 0.38
CYP11B2 P19099 1/20 0.38
RXRA P19793 1/20 0.37
FFAR4 Q5NUL3 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30501981 0.90 BRD4 (0.48) BRD4NPC1HPGDRAB9ASMN1; SMN2
SCHEMBL4664584 0.87 BRD4 (0.43) BRD4NPC1HPGDRAB9ASMN1; SMN2
SCHEMBL4662880 0.85 BRD4 (0.50) BRD4NPC1HPGDRAB9ASMN1; SMN2
SCHEMBL4664857 0.80 GCK (0.40) BRD4NPC1RAB9ASMN1; SMN2SRD5A1
SCHEMBL3267227 0.80 BRD4 (0.45) BRD4NPC1HPGDRAB9ASMN1; SMN2
SCHEMBL1942215 0.79 BRD4 (0.44) BRD4HPGDSMN1; SMN2LRRK2HDAC1
SCHEMBL4663206 0.78 ALPL (0.34) BRD4NPC1RAB9ASMN1; SMN2F2
SCHEMBL4662927 0.78 BRD4 (0.48) BRD4NPC1HPGDRAB9ASMN1; SMN2
SCHEMBL31513743 0.78 F2 (0.46) BRD4F2F10HDAC1HDAC6
SCHEMBL4663172 0.77 BRD4 (0.47) BRD4NPC1HPGDRAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080113963-A1 Cyclic benzimidazoles ALTANA PHARMA AG (DE) 2008-05-15 US disclosed
US-7307084-B2 Cyclic benzimidazoles ALTANA PHARMA AG (DE) 2007-12-11 US disclosed
US-20060194968-A1 Cyclic benizimidazoles ALTANA PHARMA AG (DE) 2006-08-31 US disclosed
EP-1613626-A1 CYCLIC BENZIMIDAZOLES ALTANA Pharma AG (DE) 2006-01-11 EP disclosed
WO-2004087701-A1 CYCLIC BENZIMIDAZOLES ALTANA PHARMA AG (DE) 2004-10-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060194968-A1 Cyclic benizimidazoles VIP, SI, GIPR BRD4 85/4885NPC1 2772/4885HPGD 548/4885
US-20080113963-A1 Cyclic benzimidazoles VIP, GIPR, SI BRD4 1068/4885NPC1 2631/4885HPGD 810/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.